Yenos Analytical Launches the Yenos Test, First-of-its-Kind Multi-Cancer Early Detection Urine Test

Only MCED test to use a urine sample collected at home instead of blood draw.-Only MCED to detect stage I/II cancers with 97% sensitivity and 97% specificity.-Offered as a laboratory-developed test at $749-Nationwide access enabled through FedEx with prepaid shipping both ways. Yenos Analytical LLC, a leader in cancer diagnostics using microRNA quantification and nanopore-array […]

Unilog.sc Named as a Challenger in Inaugural 2025 Gartner(R) Magic Quadrant(TM) for Fourth-Party Logistics (4PL)

LYNBROOK, N.Y., Dec. 09, 2025 (GLOBE NEWSWIRE) — Unilog.sc, a leading global supply chain design and execution company, has been named a Challenger in the inaugural 2025 Gartner(R) Fourth-Party Logistics (4PL) Magic Quadrant, published on December 1st, 2025. Gartner evaluated providers on their ability to execute and completeness of vision, which have seven and eight

Unilog.sc Named as a Challenger in Inaugural 2025 Gartner(R) Magic Quadrant(TM) for Fourth-Party Logistics (4PL)

Unilog.sc Named as a Challenger in Inaugural 2025 Gartner(R) Magic Quadrant(TM) for Fourth-Party Logistics (4PL) Unilog recognized for its Vision and Execution GlobeNewswire December 09, 2025 LYNBROOK, N.Y., Dec. 09, 2025 (GLOBE NEWSWIRE) — Unilog.sc, a leading global supply chain design and execution company, has been named a Challenger in the inaugural 2025 Gartner(R) Fourth-Party

Toews Asset Management Promotes Christopher Collins to Regional Vice President, Eastern Territory

Toews Asset Management, a national risk-managed boutique investment advisor with $1B in assets under management and administration, is pleased to announce the appointment of Christopher Collins as its new Regional Vice President for the high priority Eastern Territory. Collins promotion from Toews' Internal Wholesaler to sales leadership will play a key role in driving growth

Dairy Runway’s Fourth Cohort Caps Entrepreneurship Training with Virtual Pitch

The fourth cohort of Dairy Runway, an entrepreneurship program supporting early-stage food innovators developing value-added dairy products, participated in a virtual pitch session Friday, Dec. 5, marking the culmination of the cohort's experience. The program is administered by Cornell University's Center for Regional Economic Advancement (CREA) and funded by the New York State Dairy Promotion

What American Drivers Really Want, and How VinFast Is Delivering It

As America's electric vehicle market matures and moves beyond its early stage of excitement, a new pattern in consumer behavior is emerging. Drivers are no longer persuaded by novelty alone, they are searching for a deeper sense of certainty – reliability, long-term value, and emotional reassurance. In this evolving landscape, VinFast, the rising EV manufacturer

Wonder Sciences Brings 190 Global Leaders to Antarctica for a Landmark Summit on the Future of Mental Healthcare and Advanced AI

A first-of-its-kind scientific expedition examines the next era of precision mental healthcare, psychedelic science and psychedelic-assisted therapy, and AI-driven clinical innovation. In one of the most remote and scientifically revealing environments on Earth, Wonder Sciences together with Insider Expeditions convened 190 leading researchers, clinicians, technologists, and policymakers across mental healthcare, psychedelic science, advanced AI, neuroscience,

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer

(NASDAQ:AKTX), Data highlights the ability of Akari's Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates The K-Ras G12V mutation is the oncogenic driver for 1/3 of all pancreatic ductal adenocarcinoma (PDAC), the most common form of

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer GlobeNewswire December 09, 2025 Data highlights the ability of Akari's Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates

DIVERSEartLA Returns to LA Art Show to Examine How Biennials Shape the Evolving Art Landscape

Marking its 31st year, LA Art Show returns to the LA Convention Center January 7-11, 2026. Led by director and producer Kassandra Voyagis, the fair will feature more than 90 exhibitors. Its non-commercial platform, DIVERSEartLA, curated by Marisa Caichiolo, returns with “The Biennials and Art Institutions in the Contemporary Art Ecosystem,” examining how contemporary art

Scroll to Top